DFTX DT120 ODT 100 μg Phase 3 results support 2027 NDA plans
Panorama Phase 3 data for DT120 ODT 100 μg in GAD showed rapid, robust, durable efficacy versus placebo and a favorable safety profile, supporting dose-response and 2027 NDA plans.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.